Marker Therapeutics (NASDAQ:MRKR) Announces Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Marker Therapeutics (NASDAQ:MRKR) posted its earnings results on Monday. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14), Zacks reports. The firm had revenue of $1.22 million for the quarter, compared to analysts’ expectations of $5.25 million. Marker Therapeutics had a negative return on equity of 89.63% and a negative net margin of 179.74%.

Marker Therapeutics Stock Down 7.3 %

Marker Therapeutics stock opened at $1.14 on Wednesday. Marker Therapeutics has a 12-month low of $1.10 and a 12-month high of $5.99. The firm’s 50-day moving average is $1.59 and its two-hundred day moving average is $2.71.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MRKR. WBB Securities reiterated a “strong-buy” rating and issued a $12.50 price objective on shares of Marker Therapeutics in a research report on Tuesday. Brookline Capital Management raised shares of Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th. Finally, Canaccord Genuity Group assumed coverage on shares of Marker Therapeutics in a research note on Wednesday, March 5th. They set a “buy” rating and a $8.00 price objective for the company.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.